Prelude Therapeutics

NASDAQ: PRLD · Real-Time Price · USD
0.84
-0.10 (-11.11%)
At close: Aug 15, 2025, 3:59 PM
0.87
4.05%
After-hours: Aug 15, 2025, 04:54 PM EDT

Prelude Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
7M n/a n/a n/a
Cost of Revenue
n/a 1.17M 3.04M 2.24M
Gross Profit
7M -1.17M -3.04M -2.24M
Operating Income
-139.71M -132.28M -123.54M -113.73M
Interest Income
n/a n/a n/a n/a
Pretax Income
-127.17M -121.83M -115.44M -111.69M
Net Income
-127.17M -121.83M -107.34M -110.78M
Selling & General & Admin
28.72M 28.88M 30.65M 26.96M
Research & Development
118M 103.39M 92.89M 86.78M
Other Expenses
n/a n/a 8.1M 2.04M
Operating Expenses
146.71M 132.28M 123.54M 113.73M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
146.71M 132.28M 123.54M 113.73M
Income Tax Expense
n/a n/a -8.1M -915K
Shares Outstanding (Basic)
75.81M 60.36M 47.37M 47.6M
Shares Outstanding (Diluted)
75.81M 60.36M 47.37M 47.6M
EPS (Basic)
-1.68 -2.02 -2.27 -2.33
EPS (Diluted)
-1.68 -2.02 -2.27 -2.33
EBITDA
-139.71M -131.11M -122.22M -112.82M
EBIT
-139.71M -132.28M -123.54M -113.73M
Depreciation & Amortization
n/a 1.17M 3.04M 2.24M